Severe Eosinophilic Asthma: A Roadmap to Consensus

European Respiratory Journal - United Kingdom
doi 10.1183/13993003.00634-2017
Full Text
Abstract

Available in full text

Date
Authors
Publisher

European Respiratory Society (ERS)

Related search

Reslizumab: Add-On Therapy for Severe Eosinophilic Asthma

Prescriber
Pharmacology
2017English

Benralizumab for the Treatment of Severe Eosinophilic Asthma

Prescriber
Pharmacology
2018English

Severe Eosinophilic Asthma and Aspirin-Exacerbated Respiratory Disease Associated to Eosinophilic Gastroenteritis Treated With Mepolizumab: A Case Report

Allergy, Asthma and Clinical Immunology
ImmunologyPulmonaryAllergyRespiratory Medicine
2020English

Mepolizumab for Severe Refractory Eosinophilic Asthma: Evidence to Date and Clinical Potential

Therapeutic Advances in Chronic Disease
Medicine
2016English

Pharmacoeconomic Analysis of Therapy With Reslizumab in Severe Eosinophilic Asthma

Pulmonologiya
PulmonaryRespiratory Medicine
2018English

New Sociology for Better Understanding Severe Eosinophilic Asthma: Introducing the SOCS Family

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2016English

The Clinical Profile of Benralizumab in the Management of Severe Eosinophilic Asthma

Therapeutic Advances in Respiratory Disease
PulmonaryRespiratory MedicinePharmacology
2016English

Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma

Clinical Pharmacology and Therapeutics
Pharmacology
2019English

Prs55 - Cost-Effectiveness of Mepolizumab in Severe Eosinophilic Asthma Patients in France

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy